CD38 and Miyoshi myopathy: Furthermore, it would be interesting to periodically access CD38 expression in patients with relapsed/refractory MM and daratumumab retreatment would have more sense if the CD38 expression is pronounced and if a longer time had passed since the previous daratumumab usage.